Callan JMB Enters Agreement to Host Oral Drug Delivery Manufacturing at Texas cGMP Facility

Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare indust...

November 14, 2025 | Friday | News
AtomVie and Ariceum Achieve First Clinical Dosing of 225Ac-SSO110 in SANTANA-225 Trial

  AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical CDMO, announced that it has successfully supplied the first dose of Ariceum The...

November 13, 2025 | Thursday | News
Pixelgen Technologies and Carolina Molecular Partner to Bring 3D Protein Interactomics to U.S. Researchers

Carolina Molecular Inc., a leading molecular testing services laboratory, and Pixelgen Technologies AB announced  a partnership to expand access to ...

November 13, 2025 | Thursday | News
March Biosciences Receives FDA RMAT Designation for MB-105 CAR-T in T-Cell Lymphoma

- March Biosciences (March Bio), a clinical stage biotechnology company developing cell therapies for hard-to-treat cancers,  announced that the U.S...

November 12, 2025 | Wednesday | News
Gnome Sciences Identifies Cancer Drug That Prevented ALS in Preclinical Study

Gnome Sciences, a molecular pathology and translational research services company, announced a significant advance in the fight against ALS (amyotrophic ...

November 12, 2025 | Wednesday | News
LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis

 LISCure Biosciences ("LISCure"), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in a global Phase 2 cl...

November 11, 2025 | Tuesday | News
Nurami Medical Advances Artifix® Toward First-in-Human Trials With Successful Phase 1 Completion

Nurami Medical, a company developing next-generation regenerative solutions for soft tissue repair, has announced successful completion of Phase 1 of...

November 11, 2025 | Tuesday | News
Vascarta and CUNY Report Preclinical Breakthrough Demonstrating STO-1 Selectively Eliminates Glioblastoma Cells

Vascarta Inc., a healthspan focused, clinical stage biopharmaceutical company advancing safe, patient friendly therapies for pain, inflammation, and, in ...

November 11, 2025 | Tuesday | News
Boehringer Ingelheim Receives FDA National Priority Voucher for HERNEXEOS® in First-Line HER2-Mutant NSCLC

  The U.S. Food & Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS® (zongertinib tablets...

November 10, 2025 | Monday | News
Repatha Reduces Risk of Heart Attack by 36% in Phase 3 VESALIUS-CV Study

Study Also Shows 36% Reduction in Risk of Heart Attack  Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Hea...

November 10, 2025 | Monday | News
Merck Presents Phase 3 Data Showing Enlicitide Achieved Up to 60% LDL-C Reduction With Placebo-Like Safety

Enlicitide, designed to deliver antibody-like efficacy, has the potential to be the first approved oral PCSK9 inhibitor to lower LDL-C with a safety pr...

November 10, 2025 | Monday | Reports
Dupixent Delivers First Positive Phase 3 Results in Allergic Fungal Rhinosinusitis

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal cong...

November 10, 2025 | Monday | News
Facet Life Sciences and XCancer Form Strategic Partnership to Accelerate Development of Theranostic Radiopharmaceuticals

Facet Life Sciences, a leader in regulatory strategy and drug development services, announced a strategic partnership with XCancer®, a global leader ...

November 07, 2025 | Friday | News
Jupiter Neurosciences Receives FDA IND Clearance to Initiate Phase 2a Trial of JOTROL™ in Parkinson’s Disease

Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic pla...

November 06, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close